Adenovirus-based vaccine prevents pneumonia in ferrets challenged with the SARS coronavirus and stimulates robust immune responses in macaques

Vaccine. 2007 Jul 9;25(28):5220-31. doi: 10.1016/j.vaccine.2007.04.065. Epub 2007 May 7.


A ferret model of severe acute respiratory syndrome (SARS)-CoV infection was used to evaluate the efficacy of an adenovirus vaccine. Animals were subjected to heterologous prime-boost using vectors from human serotype 5 and chimpanzee derived adenoviruses (human AdHu5 and chimpanzee AdC7) expressing spike protein followed by intranasal challenge with SARS-CoV. Vaccination led to a substantial reduction in viral load and prevented the severe pneumonia seen in unvaccinated animals. The same prime-boost strategy was effective in rhesus macaques in eliciting SARS-CoV specific immune responses. These data indicate that a heterologous adenovirus-based prime-boost vaccine strategy could safely stimulate strong immunity that may be needed for complete protection against SARS-CoV infection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenoviridae / immunology*
  • Administration, Intranasal
  • Animals
  • Antigens, Viral / immunology
  • B-Lymphocytes / immunology
  • Disease Models, Animal
  • Ferrets
  • Humans
  • Immunization, Secondary / methods
  • Lung / immunology
  • Lung / pathology
  • Lung / virology
  • Macaca mulatta
  • Pneumonia / immunology*
  • Pneumonia / prevention & control
  • Severe Acute Respiratory Syndrome / immunology*
  • Severe Acute Respiratory Syndrome / prevention & control
  • Severe acute respiratory syndrome-related coronavirus / growth & development
  • Severe acute respiratory syndrome-related coronavirus / immunology*
  • T-Lymphocytes / immunology
  • Vaccination / methods
  • Viral Vaccines / administration & dosage
  • Viral Vaccines / immunology*


  • Antigens, Viral
  • Viral Vaccines